Robert Pilarski1, Randall Burt, Wendy Kohlman, Lana Pho, Kristen M Shannon, Elizabeth Swisher. 1. Affiliations of authors: Division of Human Genetics, Department of Internal Medicine and Comprehensive Cancer Center, The Ohio State University, Columbus, OH (RP); Huntsman Cancer Institute, Salt Lake City, UT (RB, WK, LP); University of Utah School of Medicine, Salt Lake City, UT (RB, WK); Department of Dermatology, University of Utah, Salt Lake City, UT (LP); Massachusetts General Hospital Cancer Center, Center for Cancer Risk Assessment, Boston, MA (KMS); University of Washington Medical Center/Seattle Cancer Care Alliance, Seattle, WA (ES).
Abstract
BACKGROUND: PTEN hamartoma tumor syndrome (PHTS) refers to a spectrum of disorders caused by mutations in the phosphatase and tensin homolog (PTEN) gene. Diagnostic criteria for Cowden syndrome, the principal PTEN-related disorder, were first established in 1996 before the identification of the PTEN gene and the ability to molecularly confirm a clinical diagnosis. These consortium criteria were based on clinical experience and case reports in the existing literature, with their inherent selection biases. Although it was initially reported that approximately 80% of patients with Cowden syndrome had an identifiable germline PTEN mutation, more recent work has shown these diagnostic criteria to be far less specific. In addition, increasing evidence has documented the association of a broader spectrum of clinical features with PTEN mutations. Our goal was to develop revised, evidence-based diagnostic criteria and to include features of the broader spectrum of PTEN-related clinical syndromes. METHODS: We performed a systematic search and review of the medical literature related to clinical features reported in individuals with a PTEN mutation and/or a related clinical diagnosis. RESULTS: We found no sufficient evidence to support inclusion of benign breast disease, uterine fibroids, or genitourinary malformations as diagnostic criteria. There was evidence to include autism spectrum disorders, colon cancer, esophageal glycogenic acanthosis, penile macules, renal cell carcinoma, testicular lipomatosis, and vascular anomalies. CONCLUSIONS: We propose revised, evidence-based criteria covering the spectrum of PTEN-related clinical disorders. Additional research on clinical features associated with PTEN mutations is warranted.
BACKGROUND:PTENhamartoma tumor syndrome (PHTS) refers to a spectrum of disorders caused by mutations in the phosphatase and tensin homolog (PTEN) gene. Diagnostic criteria for Cowden syndrome, the principal PTEN-related disorder, were first established in 1996 before the identification of the PTEN gene and the ability to molecularly confirm a clinical diagnosis. These consortium criteria were based on clinical experience and case reports in the existing literature, with their inherent selection biases. Although it was initially reported that approximately 80% of patients with Cowden syndrome had an identifiable germline PTEN mutation, more recent work has shown these diagnostic criteria to be far less specific. In addition, increasing evidence has documented the association of a broader spectrum of clinical features with PTEN mutations. Our goal was to develop revised, evidence-based diagnostic criteria and to include features of the broader spectrum of PTEN-related clinical syndromes. METHODS: We performed a systematic search and review of the medical literature related to clinical features reported in individuals with a PTEN mutation and/or a related clinical diagnosis. RESULTS: We found no sufficient evidence to support inclusion of benign breast disease, uterine fibroids, or genitourinary malformations as diagnostic criteria. There was evidence to include autism spectrum disorders, colon cancer, esophageal glycogenic acanthosis, penile macules, renal cell carcinoma, testicular lipomatosis, and vascular anomalies. CONCLUSIONS: We propose revised, evidence-based criteria covering the spectrum of PTEN-related clinical disorders. Additional research on clinical features associated with PTEN mutations is warranted.
Authors: Laura A Jansen; Ghayda M Mirzaa; Gisele E Ishak; Brian J O'Roak; Joseph B Hiatt; William H Roden; Sonya A Gunter; Susan L Christian; Sarah Collins; Carissa Adams; Jean-Baptiste Rivière; Judith St-Onge; Jeffrey G Ojemann; Jay Shendure; Robert F Hevner; William B Dobyns Journal: Brain Date: 2015-02-25 Impact factor: 13.501
Authors: Gary L Francis; Steven G Waguespack; Andrew J Bauer; Peter Angelos; Salvatore Benvenga; Janete M Cerutti; Catherine A Dinauer; Jill Hamilton; Ian D Hay; Markus Luster; Marguerite T Parisi; Marianna Rachmiel; Geoffrey B Thompson; Shunichi Yamashita Journal: Thyroid Date: 2015-07 Impact factor: 6.568
Authors: Steven Klein; Hane Lee; Shahnaz Ghahremani; Pamela Kempert; Mariam Ischander; Michael A Teitell; Stanley F Nelson; Julian A Martinez-Agosto Journal: J Med Genet Date: 2014-03-27 Impact factor: 6.318
Authors: Sarah W DeParis; Michele Bloomer; Ying Han; M Reza Vagefi; Joseph T C Shieh; David A Solomon; James Grenert; Alejandra G de Alba Campomanes Journal: Ocul Oncol Pathol Date: 2016-11-22
Authors: Kari L Ring; Amanda S Bruegl; Brian A Allen; Eric P Elkin; Nanda Singh; Anne-Renee Hartman; Molly S Daniels; Russell R Broaddus Journal: Mod Pathol Date: 2016-07-22 Impact factor: 7.842